Transforming JAK1 mutations exhibit differential signalling, FERM domain requirements and growth responses to interferon-γ

Biochemical Journal

Volumn 432, Issue 2, 2010, Pages 255-265

  Gordon, Geoff M ^a,b   Lambert, Que T ^a   Daniel, Kenyon G ^a   Reuther, Gary W ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

4.1 ezrin radixin moesin (FERM) domain; Acute leukaemia; Interferon ; Janus kinase 1 (JAK1); Transformation; Tyrosine kinase

Indexed keywords

ACUTE LEUKAEMIA; EZRIN/RADIXIN/MOESIN; JANUS KINASE; TRANSFORMATION; TYROSINE KINASE;

AMINO ACIDS; ANTIBIOTICS; GLYCOPROTEINS; PHOSPHORYLATION;

CHEMICAL ACTIVATION;

GAMMA INTERFERON; JANUS KINASE 1; MUTANT PROTEIN; STAT1 PROTEIN;

ACUTE LEUKEMIA; AMINO ACID SUBSTITUTION; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVATION; ENZYME STRUCTURE; FERM FOMAIN; GENE DELETION; GENE MUTATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SCREENING; SIGNAL TRANSDUCTION;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; BINDING SITES; CLONING, MOLECULAR; CYTOSKELETAL PROTEINS; ENZYME ACTIVATION; HEK293 CELLS; HUMANS; IMMUNOBLOTTING; INTERFERON-GAMMA; JANUS KINASE 1; MUTAGENESIS; MUTAGENESIS, SITE-DIRECTED; MUTATION; PLASMIDS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SIGNAL TRANSDUCTION;

EID: 78649584257     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20100774     Document Type: Article

References (40)

1. Haan, C., Kreis, S., Margue, C. and Behrmann, I. (2006) Jaks and cytokine receptors: an intimate relationship. Biochem. Pharmacol. 72, 1538-1546
2. Rane, S. G. and Reddy, E. P. (2000) Janus kinases: components of multiple signaling pathways. Oncogene 19, 5662-5679
3. Wilks, A. F., Harpur, A. G., Kurban, R. R., Ralph, S. J., Zurcher, G. and Ziemiecki, A. (1991) Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol. Cell. Biol. 11, 2057-2065
4. Saharinen, P., Vihinen, M. and Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459
5. Lindauer, K., Loerting, T., Liedl, K. R. and Kroemer, R. T. (2001) Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulation. Protein Eng. 14, 27-37
6. Vainchenker, W., Dusa, A. and Constantinescu, S. N. (2008) JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Semin. Cell Dev. Biol. 19, 385-393
7. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061 (Pubitemid 40386783)
8. James, C., Ugo, V., Le Couedic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148 (Pubitemid 40663494)
9. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M. and Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790
10. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397
11. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B. and Zhao, Z. J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280, 22788-22792
12. Lee, T. S., Ma, W., Zhang, X., Giles, F., Kantarjian, H. and Albitar, M. (2009) Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations. Cancer 115, 1692-1700
13. Lu, X., Huang, L. J. and Lodish, H. F. (2008) Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283, 5258-5266
14. Haan, C., Behrmann, I. and Haan, S. (2010) Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J. Cell Mol. Med. 14, 504-527
15. Flex, E., Petrangeli, V., Stella, L., Chiaretti, S., Hornakova, T., Knoops, L., Ariola, C., Fodale, V., Clappier, E., Paoloni, F. et al. (2008) Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J. Exp. Med. 205, 751-758
16. Jeong, E. G., Kim, M. S., Nam, H. K., Min, C. K., Lee, S., Chung, Y. J., Yoo, N. J. and Lee, S. H. (2008) Somatic mutations of JAK1 and JAK3 in acute leukemias and solid cancers. Clin. Cancer Res. 14, 3716-3721
17. Xiang, Z., Zhao, Y., Mitaksov, V., Fremont, D. H., Kasai, Y., Molitoris, A., Ries, R. E., Miner, T. L., McLellan, M. D., DiPersio, J. F. et al. (2008) Identification of somatic JAK1 mutations in patients with acute myeloid leukemia. Blood 111, 4809-4812
18. Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X. et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 106, 9414-9418
19. Tyner, J. W., Deininger, M. W., Loriaux, M. M., Chang, B. H., Gotlib, J. R., Willis, S. G., Erickson, H., Kovacsovics, T., O'Hare, T., Heinrich, M. C. and Druker, B. J. (2009) RNAi screen for rapid therapeutic target identification in leukemia patients. Proc. Natl. Acad. Sci. U.S.A. 106, 8695-8700
20. Asnafi, V., Le Noir, S., Lhermitte, L., Gardin, C., Legrand, F., Vallantin, X., Malfuson, J. V., Ifrah, N., Dombret, H. and Macintyre, E. (2010) JAK1 mutations are not frequent events in adult T-ALL: a GRAALL study. Br. J. Haematol. 148, 178-179
21. Koh, E. Y., Chen, T. and Daley, G. Q. (2002) Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 30, e142
22. Pradhan, A., Lambert, Q. T., Griner, L. N. and Reuther, G. W. (2010) Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J. Biol. Chem. 285, 16651-16663
23. Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J. and Lucet, I. S. (2009) Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387, 219-232
24. Reference deleted
25. Knoops, L., Hornakova, T., Royer, Y., Constantinescu, S. N. and Renauld, J. C. (2008) JAK kinases overexpression promotes in vitro cell transformation. Oncogene 27, 1511-1519
26. Staerk, J., Kallin, A., Demoulin, J. B., Vainchenker, W. and Constantinescu, S. N. (2005) JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor. J. Biol. Chem. 280, 41893-41899
27. Dusa, A., Staerk, J., Elliott, J., Pecquet, C., Poirel, H. A., Johnston, J. A. and Constantinescu, S. N. (2008) Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J. Biol. Chem. 283, 12941-12948
28. Lu, X., Levine, R., Tong, W., Wernig, G., Pikman, Y., Zarnegar, S., Gilliland, D. G. and Lodish, H. (2005) Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Proc. Natl. Acad. Sci. U.S.A. 102, 18962-18967
29. Haan, C., Is'harc, H., Hermanns, H. M., Schmitz-Van De Leur, H., Kerr, I. M., Heinrich, P. C., Grotzinger, J. and Behrmann, I. (2001) Mapping of a region within the N terminus of Jak1 involved in cytokine receptor interaction. J. Biol. Chem. 276, 37451-37458
30. Meraz, M. A., White, J. M., Sheehan, K. C., Bach, E. A., Rodig, S. J., Dighe, A. S., Kaplan, D. H., Riley, J. K., Greenlund, A. C., Campbell, D. et al. (1996) Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84, 431-442
31. Roll, J. D. and Reuther, G. W. (2010) CRLF2 and JAK2 in B-Progenitor acute lymphoblastic leukemia: a novel association in oncogenesis. Cancer Res. 70, 7347-7352
32. Huse, M. and Kuriyan, J. (2002) The conformational plasticity of protein kinases. Cell 109, 275-282
33. Boggon, T. J., Li, Y., Manley, P. W. and Eck, M. J. (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106, 996-1002 (Pubitemid 41076445)
34. Hornakova, T., Chiaretti, S., Lemaire, M. M., Foa, R., Ben Abdelali, R., Asnafi, V., Tartaglia, M., Renauld, J. C. and Knoops, L. (2010) ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 115, 3287-3295
35. Haan, S., Margue, C., Engrand, A., Rolvering, C., Schmitz-Van de Leur, H., Heinrich, P. C., Behrmann, I. and Haan, C. (2008) Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J. Immunol. 180, 998-1007
36. Zhou, Y. J., Chen, M., Cusack, N. A., Kimmel, L. H., Magnuson, K. S., Boyd, J. G., Lin, W., Roberts, J. L., Lengi, A., Buckley, R. H. et al. (2001) Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol. Cell 8, 959-969
37. Zhao, L., Ma, Y., Seemann, J. and Huang, L. J. (2010) A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F). Biochem. J. 426, 91-98
38. Hayashi, T., Kobayashi, Y., Kohsaka, S. and Sano, K. (2006) The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-γ inducibility of TAP1 and LMP2. Oncogene 25, 4016-4026
39. Rossi, M. R., Hawthorn, L., Platt, J., Burkhardt, T., Cowell, J. K. and Ionov, Y. (2005) Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis. Cancer Genet. Cytogenet. 161, 97-103
40. Sexl, V., Kovacic, B., Piekorz, R., Moriggl, R., Stoiber, D., Hoffmeyer, A., Liebminger, R., Kudlacek, O., Weisz, E., Rothammer, K. and Ihle, J. N. (2003) Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. Blood 101, 4937-4943